Further studies have demonstrated that NLRP3 deficiency downregulates glucose transporter protein 1 (GLUT1) expression and glycolytic activity in MSCs, leading to decreased IL-10 production and reduced therapeutic efficacy against DSS-induced colitis. The gene discussed is NLRP3; the disease is colitis.